news
Servier acquires treatment for autism genetic cause Fragile X syndrome
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
List view / Grid view
Servier
article
Cleanroom microbiology: single-temperature incubation for EM
Single-temperature incubation has been discussed for a long time in the pharmaceutical industry but only a few sites have implemented this system. Here, Guillaume Pinon, Head of the Microbiology Lab at Servier, discusses the use of single-temperature incubation in an aseptic production facility, outlining the regulatory considerations, strategic approach, challenges…
article
QA/QC Microbiology In-Depth Focus 2024
This in-depth focus features articles on single temperature incubation, endotoxin standards and aseptic connections in pharmaceutical manufacturing.
article
European Pharmaceutical Review Issue 3 2024
European Pharmaceutical Review Issue 3 includes articles on microbiology, downstream bioprocessing and drug development. Register your details now to download this exclusive content.
article
Outsourcing regulatory activities in pharma
Here, EPR's Caroline Peachey explores some key considerations, approaches and strategies for pharmaceutical companies looking to outsource regulatory activities.
article
Servier: Bringing innovation to patients
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
article
21st Anniversary Supplement
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
news
First patient treated in Phase I UCART19 trial in paediatric B-ALL
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
news
EC grants marketing authorisation to Lonsurf in mCRC
27 April 2016 | By Victoria White, Digital Content Producer
The decision from the EC was based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study...
news
Servier exercises options to acquire worldwide rights to UCART19
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
news
Amgen and Servier complete product collaboration transaction
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
news
Amgen and Servier announce product collaboration
9 July 2013 | By Amgen
Amgen obtains US rights to novel EU-approved cardiovascular therapy; Servier receives option for omecamtiv mecarbil in Europe...
news
Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
